Author: @admin

Post

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp

SCYNEXIS Presents Interim Analysis from FURI at Virtual IDWeek 2021 Showing Favorable Therapeutic Response in Severe Hospital-Based Fungal Infections Treated with Oral Ibrexafungerp Subpopulation analysis of 74 patients from ongoing Phase 3 FURI study demonstrated similar efficacy against multiple serious fungal infections JERSEY CITY, N.J., Sept. 29, 2021 (GLOBE...

September 29, 2021September 29, 2021by In News
Post

Cidara Therapeutics to Present New Data for Rezafungin at TIMM Congress

SAN DIEGO, Sept. 29, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will present new clinical and non-clinical data in two poster presentations at the 10th Congress on Trends in Medical Mycology...

September 29, 2021September 29, 2021by In News
Post

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the Company held...

September 28, 2021September 28, 2021by In News
Post

Iterum Therapeutics to Present Data at IDWeek 2021

DUBLIN, Ireland and CHICAGO, Sept. 28, 2021 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced a data presentation at...

September 28, 2021September 28, 2021by In News
Post

Cidara Therapeutics to Present New Data for Rezafungin at IDWeek 2021

SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases, today announced that it will present new clinical and non-clinical data in three on-demand poster presentations, including data on rezafungin clinical safety and pharmacokinetics...

September 27, 2021September 27, 2021by In News
Post

Nabriva Therapeutics to Present Data at IDWeek 2021

DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced data presentation at the Infectious Disease Society of America (IDSA) IDWeek™ 2021, taking place virtually from September 29 – October...

September 24, 2021September 24, 2021by In News
Post

Entasis Therapeutics to Participate in the Cantor Fitzgerald Virtual Global Healthcare Conference

WALTHAM, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today that management will participate in the upcoming Cantor Fitzgerald Virtual Global Healthcare Conference to be held September 27-30, 2021. Details of the Company’s participation can be...

September 23, 2021September 23, 2021by In News
Post

SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years

SCYNEXIS Announces U.S. Availability of BREXAFEMME® (ibrexafungerp tablets), the First New Antifungal Class of Therapy Approved by the U.S. FDA for Vaginal Yeast Infections in More Than 20 Years First and only oral non-azole treatment option approved for vaginal yeast infections is now available in pharmacies including cloud-based pharmacy...

September 22, 2021September 22, 2021by In News
Post

Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin)

Melinta Therapeutics Announces Two Key Milestones Expanding Reimbursement and Access for KIMYRSA™ (oritavancin) KIMYRSA™ Receives Product-Specific J-Code and Transitional Pass-Through Status from CMS MORRISTOWN, N.J., Sept. 20, 2021 (Businesswire) — Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic...

September 21, 2021September 21, 2021by In News
Post

Profile of Entasis Therapeutics ETX0462 Candidate Published in the Journal Nature

Publication Details the Discovery and Preclinical Profile of ETX0462, a First-in-Class Candidate Against Multidrug-Resistant Pathogens WALTHAM, Mass., Sept. 15, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced the publication of a profile of the company’s ETX0462 candidate...

September 15, 2021September 15, 2021by In News